Warning Labels Updates on MRI Gadolinium-Based Contrast Agents

Gadolinium-based MRI contrast agents have been proving to carry great risk of nephrogenic systemic fibrosis (NSF). This has caused the U.S. Food and Drug Administration (FDA) to announce warning labels updates on three of these agents. The three agents are Magnevist, sold by Bayer Healthcare Pharmaceuticals of Wayne, NJ; Omniscan, marketed by GE Healthcare of Chalfont St. Giles, U.K.; and Optimark, sold by Covidien of Dublin, Ireland.